Nasdaq

PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company

10-07-2017

Oslo (Norway), 10 July 2017 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company, initiated in September 2015. The extended evaluation period spans over six months, until the end of 2017, and may be further extended.

The pharma company is one of the global leaders in nucleic acid therapeutics. The aim of the extension is to further evaluate the synergistic effects of both parties' technology platforms and to determine whether PCI Biotech's fima
NAc
technology has the potential to enhance the therapeutic effect of the partner's nucleic acid therapeutic compounds.

The previous agreement covered
in vitro
studies, while this extension is supported by an expansion of the preclinical research collaboration agreement to cover evaluation of technological compatibility and synergy based on
in vivo
studies. The companies will evaluate the data generated in this research collaboration and explore the potential for a further partnership based on this outcome.

Contact information:

Per Walday, CEO

pw@pcibiotech.no

Mobile: +47 917 93 429

About PCI Biotech

PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms:

fima
Chem

(enhancement of chemotherapeutics for localised treatment of cancer),

fima
Vacc

(T-cell induction technology for therapeutic vaccination), and

fima
NAc

(nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company's lead

fima
Chem

programme consists of a clinical Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products.

fima
Vacc

applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies.

fima
NAc

utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit:
www.pcibiotech.com

Forward-looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: PCI Biotech Holding via GlobeNewswire

HUG#2119229